Results 31 to 40 of about 31,914 (284)

Percutaneous Left Atrial Appendage Occlusion in Comparison to Non‐Vitamin K Antagonist Oral Anticoagulant Among Patients With Atrial Fibrillation

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2022
Background This study aimed to compare percutaneous left atrial appendage occlusion (LAAO) with non‐vitamin K antagonist oral anticoagulants among patients with atrial fibrillation. Methods and Results Using a US administrative database, 562 850 patients
Peter A. Noseworthy, Holly K. Van Houten, Harlan M. Krumholz, David M. Kent, Neena S. Abraham, Jonathan Graff‐Radford, Mohamad Alkhouli, Henry J. Henk, Nilay D. Shah, Bernard J. Gersh, Paul A. Friedman, David R. Holmes, Xiaoxi Yao   +12 more
doaj   +1 more source

Real-practice thromboprophylaxis in atrial fibrillation [PDF]

, 2017
This retrospective observational study was based on databases of the Local Health Authority of Treviso, Italy. It evaluated the prevalence and the effectiveness of oral anticoagulation treatment (OAT) for the management of nonvalvular atrial fibrillation
Bettiol, Alessandra, Bolcato, Jenny, Chinellato, Alessandro, Deambrosis, Paola, Franchin, Giulia, Giusti, Pietro, Pellizzari, Michele, Pirolo, Roberta, Themistoclakis, Sakis   +8 more
core   +2 more sources

Periodontitis and atherosclerotic cardiovascular disease: A critical appraisal

Periodontology 2000, EarlyView., 2023
Abstract In spite of intensive research efforts driving spectacular advances in terms of prevention and treatments, cardiovascular diseases (CVDs) remain a leading health burden, accounting for 32% of all deaths (World Health Organization. “Cardiovascular Diseases (CVDs).” WHO, February 1, 2017, https://www.who.int/news‐room/fact‐sheets/detail ...
Maria Clotilde Carra, Hélène Rangé, Giuseppina Caligiuri, Philippe Bouchard   +3 more
wiley   +1 more source

Real-world cost-effectiveness analysis of NOACs versus VKA for stroke prevention in Spain.

PLoS ONE, 2022
AimsA Markov model was adapted to assess the real-world cost-effectiveness of rivaroxaban, dabigatran and apixaban. Each of these non-vitamin K antagonist oral anticoagulants was compared with vitamin K antagonist for stroke prevention in patients with ...
Carlos Escobar Cervantes, Julio Martí-Almor, Alejandro Isidoro Pérez Cabeza, Kevin Bowrin, Aleix Llorac Moix, Mar Genís Gironès, David Gasche, Aurélie Millier, Jean Tardu, Mondher Toumi, Jean-Baptiste Briere   +10 more
doaj   +2 more sources

How we treat bleeding associated with direct oral anticoagulants [PDF]

, 2016
Direct oral anticoagulants are at least as effective as vitamin K antagonists for the prevention and treatment of thromboembolism. Unfortunately, differently from vitamin K antagonists, they have the great drawback of lacking specific antidotes in the ...
Franchini, Massimo, Liumbruno, Giancarlo M, Marano, Giuseppe, Pupella, Simonetta, VAGLIO, Stefania   +4 more
core   +1 more source

Current clinician perspective on non-vitamin K antagonist oral anticoagulant use in challenging clinical cases. [PDF]

, 2020
OBJECTIVE: The evolution of non-vitamin K antagonist anticoagulants (NOACs) has changed the horizon of stroke prevention in atrial fibrillation (SPAF).
Acar, RD, Akgün, T, Camm, AJ, Emren, V, Kanat, S, Karacağlar, E, Kepez, A, Kul, Ş, Tülüce, K, Türk, UÖ, Yakar Tülüce, S, Özel, E, Şimşek, E   +12 more
core   +1 more source

Non-vitamin K antagonist oral anticoagulants and heart failure

Archives of Cardiovascular Diseases, 2016
Thromboembolism contributes to morbidity and mortality in patients with heart failure (HF), and atrial fibrillation (AF) is one of the main factors promoting this complication. As they share many risk factors, HF and AF frequently coexist, and patients with both conditions are at a particularly high risk of thromboembolism.
Isnard, R., Bauer, F., Cohen-Solal, A., Damy, T., Donal, Erwan, Galinier, M., Hagège, A., Jourdain, P., Leclercq, Christophe, Sabatier, Rodolphe, Trochu, Jean-Noël, Cohen, A.   +11 more
openaire   +3 more sources

Off‐target effects of oral anticoagulants – vascular effects of vitamin K antagonist and non‐vitamin K antagonist oral anticoagulant dabigatran etexilate [PDF]

Journal of Thrombosis and Haemostasis, 2021
Vitamin K antagonists (VKA) and non-vitamin K oral antagonist anticoagulants (NOAC) are used in the clinic to reduce risk of thrombosis. However, they also exhibit vascular off-target effects. The aim of this study is to compare VKA and NOAC on atherosclerosis progression and calcification in an experimental setup.Female Apoe-/- mice (age 12 weeks ...
van Gorp, Rick H., Dijkgraaf, Ingrid, Bröker, Vanessa, Bauwens, Matthias, Leenders, Peter, Jennen, Danyel, Dweck, Marc R., Bucerius, Jan, Briedé, Jacco J., van Ryn, Joanne, Brandenburg, Vincent, Mottaghy, Felix, Spronk, Henri M.H., Reutelingsperger, Chris P., Schurgers, Leon J.   +14 more
openaire   +3 more sources

Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study

British medical journal, 2017
Objective To examine clinical effectiveness and safety of apixaban 2.5 mg, dabigatran 110 mg, and rivaroxaban 15 mg compared with warfarin among patients with atrial fibrillation who had not previously taken an oral anticoagulant.
P. Nielsen, F. Skjøth, M. Søgaard, J. N. Kjældgaard, G. Lip, T. Larsen   +5 more
semanticscholar   +1 more source

Stroke prevention for non-valvular atrial fibrillation: how to make the right choice of directly acting oral anticoagulants?

Российский кардиологический журнал, 2019
Patients with atrial fibrillation have a high risk of developing stroke and death, which requires constant anticoagulant support. In this regard, the physician faces the difficult task of selecting the appropriate oral anticoagulant for patient with ...
N. N. Kryukov, E. V. Sayutina, A. M. Osadchuk, M. A. Osadchuk   +3 more
doaj   +1 more source